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https://doi.org/10.1016/j.immuni.2020.11.001SUMMARYWhile antibiotics are intended to specifically target bacteria, most are known to affect host cell physiology. In
addition, some antibiotic classes are reported as immunosuppressive for reasons that remain unclear. Here,
we show that Linezolid, a ribosomal-targeting antibiotic (RAbo), effectively blocked the course of a T cell-
mediated autoimmune disease. Linezolid and other RAbos were strong inhibitors of T helper-17 cell effector
function in vitro, showing that this effect was independent of their antibiotic activity. Perturbingmitochondrial
translation in differentiating T cells, either with RAbos or through the inhibition of mitochondrial elongation
factor G1 (mEF-G1) progressively compromised the integrity of the electron transport chain. Ultimately,
this led to deficient oxidative phosphorylation, diminishing nicotinamide adenine dinucleotide concentra-
tions and impairing cytokine production in differentiating T cells. In accordance, mice lacking mEF-G1 in
T cells were protected from experimental autoimmune encephalomyelitis, demonstrating that this pathway
is crucial in maintaining T cell function and pathogenicity.INTRODUCTION
Bacteria require intact cell walls and functional ribosomes to
retain their structural and metabolic integrity. As such, inhibition
of these processes by antibiotics either kills bacteria or prevents
their growth and division (Kohanski et al., 2010; Silhavy et al.,
2010; Wilson and Doudna Cate, 2012). As eukaryotic cells do
not possess cell walls and their ribosomes are structurally
different from bacterial ribosomes, antibiotics can be used to
eradicate bacterial infections with limited toxicity to the host.
Nevertheless, some antibiotics have reported side effects,68 Immunity 54, 68–83, January 12, 2021 ª 2020 The Authors. Publis
This is an open access article under the CC BY-NC-ND license (http://such as candidiasis, anemia, bone marrow suppression, lactic
acidosis, and immunosuppression (Hellinger and Brewer,
1999; Josefsdottir et al., 2017; Mao et al., 2018; Ónodi-Nagy
et al., 2015; Prieto de Paula et al., 2017; Tedesco, 1975; Xu
et al., 2008; Zimmermann et al., 2018). Since antibiotics are often
administered to stave off infections, it is important to understand
the mechanisms governing antibiotic-mediated immunosup-
pression. Without a proper immune response, both the clear-
ance of infections and control of opportunistic pathogens are
impaired. Here, we focused on Linezolid, a ribosomal-targeting
antibiotic (RAbo) from the Oxazolidinone family, which targetshed by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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(and reserved) for the treatment of several multi-resistant bacte-
rial infections (Hashemian et al., 2018). Patients requiring Line-
zolid treatment often present in a critical state and are at
increased risk of fungal infections (Falagas and Vardakas,
2008). Moreover, Linezolid is associated with higher mortality
by Gram-negative pathogenswhen compared with Vancomycin.
As both antibiotics share a similar spectrum of action (Wilcox
et al., 2009), this discrepancy is unusual.
Linezolid, like other RAbos, inhibits mitochondrial translation
in mammalian systems and cell lines by occupying the peptidyl
transferase center of the mitochondrial ribosome (mitoribo-
some), interfering with the binding of aminoacyl-tRNAs (Leach
et al., 2007; McKee et al., 2006; Moullan et al., 2015; Zhang
et al., 2005). The assembly of electron transport chain (ETC)
complexes requires the coordinated translation of proteins by
cytosolic and mitochondrial ribosomes (Priesnitz and Becker,
2018; Richter-Dennerlein et al., 2016). By blocking mitoribo-
somes, RAbos lead to an imbalance of nuclear and mitochon-
drial-encoded ETC subunits (Houtkooper et al., 2013). This mito-
nuclear imbalance and its relevance to organismal physiology
have been previously explored in different fields of medical
research. Specifically, inhibition of mitochondrial translation
reduces adipokine secretion in adipocytes (Llobet et al., 2017),
improves worm lifespan in C. elegans (Houtkooper et al.,
2013), and selectively kills leukemia cells (Skrtic et al., 2011).
The consequence of blocking mitochondrial protein synthesis
in immune cells, however, has not been well elucidated.
Here, we show that Linezolid exhibits immunosuppressive
properties, preventing the development of self-reactive T helper
(Th) cells in a mouse model of multiple sclerosis. Linezolid and
other RAbos also inhibited Th17 cell function in vitro, showing
that immunosuppression occurred independently of their anti-
biotic activity. Mechanistically, we demonstrate that inhibiting
mitochondrial translation led to a mitonuclear imbalance in
differentiating Th17 cells, impairing mitochondrial activity and
interleukin-17 (IL-17) production. In conclusion, administration
of RAbos should be carried out with extra caution to prevent un-
desired immunosuppression. On the other hand, repurposing of
RAbos and/or development of novel drugs with a similar mech-
anism of action could potentially be used to control T cell-medi-
ated autoimmune disorders.
RESULTS
Linezolid Inhibits the Onset of a T Cell-Mediated
Autoimmune Disease
To determine if Th cell responses in vivo were altered by RAbos
treatment, we employed the murine model of T cell-mediated
autoimmunity experimental autoimmune encephalomyelitis
(EAE). Myelin oligodendrocyte glycoprotein (MOG)-immunized
mice developed classical clinical signs of EAE, presenting with
infiltrating Th cells in the central nervous system (CNS), as well
as decreased motility. Administration of a human-equivalent
dose of Linezolid limited the development and severity of EAE
symptoms (Figures 1A and 1B). This correlated with lower fre-
quency and numbers of MOG-specific IL-17- and interferon-g
(IFN-g)-producing Th cells in the CNS of Linezolid-treated mice
(Figure 1C); the frequency of FoxP3+ Th cells was not affected.Antibiotics can disturb the intestinal microbiome, which in turn
can influence the outcome of an immune response (Hagan
et al., 2019; Mestre et al., 2019; Ochoa-Reparaz et al., 2009).
To rule out that any effects mediated by Linezolid were due to
its antibacterial activity, Vancomycin, which holds a similar spec-
trum of bacterial activity as Linezolid (Mutnick et al., 2002), was
used as control. Of note, while Vancomycin inhibits cell wall syn-
thesis in bacterial cells, Linezolid inhibits prokaryotic ribosomes
(Gardete and Tomasz, 2014; Leach et al., 2007). Vancomycin-
treated mice developed severe EAE symptoms comparable to
those of the untreated group, suggesting that Linezolid’s immu-
nosuppression was due to its effect on host, and not bacte-
rial, cells.
Mitochondrial Translation Inhibition by Antibiotics
Inhibits Th17 Cell Function
Because mitochondria are of prokaryotic origin, there are simi-
larities between the bacterial and mitochondrial protein transla-
tion machineries (Degli Esposti et al., 2014); consequently,
some RAbos can also inhibit mitoribosomes. This is true not
only for Linezolid but also for other antibiotics from different clas-
ses such as Tigecycline and Thiamphenicol (Jager and Bass,
1975; Lamb et al., 2015; Yunis et al., 1973). Hence, we postu-
lated that RAbos inhibited Th17 cell function through inhibition
of mitochondrial translation. In accordance, when murine naive
CD4+ T cells were cultured under Th17 cell-polarizing conditions
in the presence of the aforementioned antibiotics, IL-17 produc-
tion was reduced in a dose-dependent manner (Figure 2A,
above). Loss of cytokine-producing cells was not caused by
death of effector cells, as viability was unaffected (Figure 2A,
below). To verify that this effect was not exclusive tomurine cells,
we differentiated human cord blood-derived naive T cells under
Th17 cell-polarizing conditions in the presence of Linezolid.
Accordingly, human Th17 cells equally presented lower IL-17
secretion (and normal viability) upon Linezolid treatment (Fig-
ure 2B). We then sought to confirm that Linezolid was able to
acutely inhibit mitochondrial translation in T cells. To this end,
we labeled mitochondrial translation products with [35S]-methio-
nine in a murine lymphoma T cell line (EL-4), pretreated for 1 h
with 100 mM of Linezolid. We observed a near-complete
blockage of [35S]-methionine incorporation into mitochondrial-
encoded ETC subunits (Figure 2C), which coincided with the
concentration required to fully inhibit IL-17 production
(Figure 2A).
The ETC is composed of five complexes, made up of several
protein subunits that must be correctly assembled. While all
complex II subunits are encoded in the nucleic DNA (nDNA)
and translated in the cytosol, complexes I, III, IV, and V contain
subunits encoded by both nDNA and mitochondrial DNA
(mtDNA). Therefore, the assembly of these complexes requires
a tight coordination between the cytosolic and mitochondrial
protein machinery. When mitochondrial translation is interrup-
ted, a mitonuclear imbalance occurs, characterized by a higher
ratio of nDNA- to mtDNA-encoded subunits (Houtkooper et al.,
2013; Moullan et al., 2015). Accordingly, Linezolid selectively
depleted the mtDNA-encoded mitochondrial-NADH-ubiquinone
oxidoreductase chain 1 (ND1) and cytochrome C oxidase I
(COX1) proteins in Th17 cells (Figure 2D). In contrast, the quantity
of nuclear-encoded succinate dehydrogenase complexImmunity 54, 68–83, January 12, 2021 69
Figure 1. Linezolid Inhibits the Onset of T Cell-Mediated Autoimmune Diseases EAE in MOG-Immunized Mice
(A) EAE clinical score of mice treated daily with Linezolid, Vancomycin, or untreated.
(B) Distribution of disease severity: no EAE: score < 1, mild EAE: 1 % score < 3, severe EAE: score R 3.
(C) Frequency (top) and number (bottom) of CD4+ T cells isolated from the central nervous system of Linezolid-treated, Vancomycin-treated, and untreatedmice.
Plots are obtained from the pooled data of three independent experiments.
(A–C) individual experiments, with error bars showing the SEM of the pooled scores (A). Statistical significance was determined using two-way ANOVA with
Bonferroni multiple corrections test compared to untreated mice. *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 2. Linezolid and Other RAbos Disrupt Th17 Effector Cell Function by Targeting Mitochondrial Translation
(A) Naive mouse CD4+ T cells cultured under Th17 cell polarizing conditions with Linezolid, Tigecycline, or Thiamphenicol. After 96 h of culture, cells were stained
for intracellular IL-17. Bar graphs represent % of IL-17+ cells amongst live CD4+ T cells (top) and % viable CD4+ T cells (bottom).
(B)HumannaiveTcellswere stained for intracellular IL-17 (right) afterbeingdifferentiated for 6days in thepresenceof the indicatedconcentrationsofLinezolid.Graphs
contain the data for each of six individual donors, indicated by connected dots: % of IL-17+ cells amongst live CD4+ T cells (left) and% of viable CD4+ T cells (right).
(legend continued on next page)
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further confirmed that Linezolid also inhibited COX1 expression
in CD4+ T cells in vivo during EAE (Figure S1A), while not mark-
edly affecting CD4+ T cell proliferation, measured by bromo-
deoxyuridine (BrdU) incorporation (Figure S1B). Linezolid is a re-
ported activator of the NLRP3 inflammasome; however, the
NLRP3 inhibitor MCC950 did not prevent Linezolid from inhibit-
ing IL-17 production (Figure 2E). These findings confirm that mi-
toribosomes—but not cytosolic ribosomes—are targets of Line-
zolid and necessary for IL-17 production in Th17 cells.
Argyrin C and Linezolid Exert Analogous Effects on
Differentiating Th17 Cells
Mitoribosomes contain 12S and 16S ribosomal RNA (rRNA), en-
coded by the MT-RNR1 and MT-RNR2 genes, respectively.
These rRNAs differ among individuals depending on their mito-
chondrial haplotype (Chen et al., 2012; H€akli et al., 2015; Pa-
cheu-Grau et al., 2010). This has the potential to modulate the
susceptibility of mitoribosomes to Linezolid (Pacheu-Grau
et al., 2013). Furthermore, as Linezolid is a reserve antibiotic, it
is difficult to conceive it as an immunosuppressant. To explore
different ways of inhibiting mitochondrial translation, we em-
ployed the Argyrin (Arg) family of compounds (Figures 3A and
S2A). Args do not bind to the mitoribosome but instead to mito-
chondrial elongation factor G1 (mEF-G1) (Nyfeler et al., 2012), an
enzyme necessary for the elongation step of mitochondrial pro-
tein synthesis (Tsuboi et al., 2009). The inhibitory capacities of
the different Args were quantified in murine naive CD4+ T cells
under Th17 cell polarizing conditions (Figures S2A and S2B).
Args A and B reduced the frequency of IL-17-producing T cells
only at the highest concentration (240 nM) tested, while Args C
and D were effective at much lower doses (24 nM). Notably,
Args F and H had no immunosuppressive activity at the tested
concentrations (Figure S2B, left). Nevertheless, Arg F still re-
tained the capacity to inhibit IL-17 production, albeit at higher
concentrations (>600 nM) (Figure S2C, left). This is consistent
with a previous report, showing that Arg F inhibits COX2 expres-
sion at doses higher than 600 nM (Chen et al., 2017). As we
observed for RAbos, cellular viability was not affected by any
Arg (Figure S2B, right and Figure S2C, right).
Considering the differences in the activity of each compound,
we focused on the most active metabolite, Arg C, for further
studies (Figure 3A). To assess whether Arg C and Linezolid exert
a general inhibitory effect on effector Th cell subset function, we
differentiated Th1, Th2, and Th17 cells under a broader range of
Arg C and Linezolid concentrations. IFN-g and IL-13 production
by murine Th1 and Th2 cells, respectively, was reduced by both
Arg C and Linezolid (Figures S3A–S3D). Similar to Linezolid, Arg
C reduced the frequency of human IL-17-producing T cells (Fig-
ure 3B, above) without affecting viability (Figure 3B, below).
mEF-G1 inhibition hampered mitochondrial translation,
measured by a near-complete blockage of [35S]-methionine(C) Mitochondrial translation products in EL-4 cells pre-incubated for 1 h with Lin
(D) SDHA, COX1, ND1, and b-actin quantified by western blot in mouse Th17 ce
(E) Naive mouse CD4+ T cells cultured under Th17 cell polarizing conditions in th
MCC950 (10 mM).
Plots are representative of two (C) or three (D) experiments, and bar graphs are po
(A, left) independent experiments, with error bars representing the SD of the poo
72 Immunity 54, 68–83, January 12, 2021incorporation in mtDNA-encoded subunits in Arg C-treated EL-
4 cells (Figure 3C). A reduction of [35S]-methionine incorporation
was also detectable after Arg F pretreatment (60 nM). However,
this impairment was partial and only observed at a concentration
100-fold higher than that required for a similar inhibition with Arg
C. This coincided with the lack of cytokine inhibition by Arg F at
60 nM (Figures S2B and S2C).
Both Linezolid and Arg C present as inhibitors of mitochondrial
protein synthesis. Despite the different molecular targets, both
inhibited Th17 cell function. To determine overall similarities be-
tween the two drugs, we performed RNA sequencing (RNA-seq)
analysis on Th17 cells exposed to Linezolid, Arg C, or vehicle for
96 h. Differential gene expression analysis showed that most
genes significantly up or downregulated by Linezolid were
equally regulated by Arg C (Figure 3D). Glycolysis and Th17
cell activation were among the top pathways downregulated
by both drugs (Figures 3E and 3F). This lower expression of
glycolytic genes was not due to lower expression of HIF1a (Fig-
ure S2D) nor was it restored by the HIF1a activator dimethylox-
allyl glycine (DMOG; Figure S2E). Genes downregulated by both
Linezolid and Arg C in the ‘‘Th17 activation pathway’’ category
included several Th17 cell-associated genes, such as Il17a,
Il17f, Il23r, Rorc, Ahr, and Il21 (Figure 3F). Of note, pathways
significantly upregulated by Linezolid and Arg Cwere associated
with cell cycle control and response to DNA damage (Figures 3E
and 3F). Overall, our results demonstrate a high degree of simi-
larity between the effects of Linezolid and Arg C on Th17 cells.
Proliferating T Cells Depend on Functional
Mitoribosomes to Maintain Their ETC Integrity and
Effector Function
Naive T cells have a lower proliferation rate and cellular respira-
tion and decreased mitochondrial proteome when compared to
activated T cells (Almeida et al., 2016; Buck et al., 2016; Liesa
and Shirihai, 2016; Ron-Harel et al., 2016). T cell activation leads
to several rounds of cell division, which require the biogenesis of
mitochondrial proteins, including those encoded by mtDNA. To
assess the reliance of differentiating T cells on mitochondrial
translation, we measured the intracellular content of ND1 and
COX1 throughout a culture with Arg C. After 48 h of treatment,
the amounts of both ND1 and COX1 decreased exclusively in
Arg C-treated differentiating Th17 cells. Arg F at 60 nM failed
to reduce the expression of either subunit (Figure 4A, left). Like
Linezolid, Arg C did not reduce the expression of the nuclear-en-
coded protein SDHA. We further hypothesized that non-prolifer-
ating naive T cells would lose their ETC subunits slower when
mitochondrial translation is inhibited. To test this, we quantified
the amount of COX1 and ND1 proteins in IL-7-maintained, Arg
C-treated, naive T cells. COX1 and ND1 were still detectable
even after 120 h of Arg C-treatment, showing that activated
T cells are more sensitive to inhibition of this pathway than their
naive counterparts (Figure 4A, right). To exclude compensatoryezolid or DMSO and radioactively labeled with [35S]-methionine.
lls after 96 h of culture.
e presence of Linezolid, with and without the NLRP3 inflammasome inhibitor
oled means of technical replicates from three (A, middle and right and E) or four
led means. *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S1.
(legend on next page)
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them to be expressed at similar amounts to controls (data
not shown).
Mitochondrial respiration supports the metabolic needs of
proliferating cells through the regeneration of electron-accepting
co-factors such as nicotinamide or flavin adenine dinucleotide
(NAD+and FAD, respectively) (Sullivan et al., 2015). Consistent
with this, both Arg C and Linezolid decreased the Th17 cell intra-
cellular NAD+/NADH ratio after 48 h of treatment (Figures 4B and
S4A). A reduced NAD+/NADH ratio leads to allosteric inhibition of
the enzyme complex pyruvate dehydrogenase, which converts
pyruvate into acetyl-CoA by decarboxylation. In these condi-
tions, pyruvate would preferentially be converted into lactate
(Holness and Sugden, 2003; Randle et al., 1963; Skrtic et al.,
2011). This was corroborated by a drop in pH of the culture me-
dium and a slight increase in lactate production by Arg C-treated
cells (Figures S4B and S4C). Deficient electron flow from NADH
to oxygen, together with a lack of mitochondrial-encoded sub-
units of complex V, F1Fo-ATPase (namely ATP6 and ATP8),
should hinder oxidative phosphorylation-derived ATP produc-
tion. Accordingly, the ADP/ATP ratio was significantly increased
in Arg C-treated cells compared to controls (Figure S4D). We
also observed that Linezolid and Arg C modestly increased the
degree of AMPK phosphorylation (pAMPK, Figure S4E). Howev-
er, exogenous ATP supplementation was unable to rescue cyto-
kine production in either of the treatment groups (Figure S4F).
As expected, Arg C and Linezolid-treated cells had a lower
basal and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP)-stimulated maximal cellular respiration (Figures 4C and
4D). The profound effects on mitochondria elicited by Arg C
were also observed by electron microscopy: in contrast to the
normal round-shaped mitochondria (Buck et al., 2016), Arg C-
treated Th17 cells had elongated mitochondria with loosened
cristae (Figure 4E). After 96 h of culture, mitochondria were
swollen or sac-shaped and had a morphology reminiscent of
that of this organelle in cells devoid of mtDNA (r0 cells) (Armand
et al., 2004). Similar to r0 cells (Appleby et al., 1999), Arg C-
treated cells were able to maintain their mitochondrial mem-
brane potential (Figure S4G). While the loss of mtDNA-encoded
subunits was evident at 48 h, IL-17 production was comparable
to controls at this time point (Figure 4F). These findings hinted
that initial Th differentiation steps were unaffected. To confirm
this, wemeasured the expression of the Th cell master transcrip-
tion factors. Indeed, Arg C did not affect the expression of T-bet,Figure 3. Inhibiting Mitochondrial Translation with Arg C Inhibits Th17
(A) Chemical structure of Arg C.
(B) Left: mouse naive CD4+ T cells cultured for 4 days under Th17 cell polarizing
intracellular IL-17 and gated on live CD4+ T cells. Bar graphs show % of IL-17+ c
CD45RO naive T cells isolated from cord blood were cultured for 6 days under T
were stained for intracellular IL-17, gated on live CD4+ T cells. Graphs contain
represent % of IL-17+ cells amongst live CD4+ cells (above) and the % of viable
(C) Mitochondrial translation products in EL-4 cells pre-incubated for 1 h with Ar
(D–F) Mouse naive CD4+ T cells were cultured under Th17 cell polarizing condit
diagrams showing the number of genes differentially up (left) or downregulated (rig
The overlapping genes are those found in both conditions (E). Top canonical path
expression of genes among three selected relevant pathways.
Results (B, left) are the pooled means of technical replicates from three independ
0.05, **p < 0.01, and ***p < 0.001. Representative results of two (C) experiments
independent experiments performed. See also Figures S2 and S3.
74 Immunity 54, 68–83, January 12, 2021GATA-3, or RORgt in Th1, Th2, and Th17 cells, respectively (Fig-
ures S5A–S5C); this strongly suggested that Arg C impaired
cytokine production rather than Th commitment. Nevertheless,
considering our transcriptomic data showed cell cycle pathways
to be dysregulated (Figures 3E and 3F), we investigated the rela-
tionship between proliferation and loss of cytokine production
caused by Arg C. Using cells labelled with CellTrace, we
observed that Arg C mildly impaired proliferation exclusively to-
ward the final stages of differentiation (Figure S5D). Importantly,
this moderate decline in cellular proliferation was not the main
cause of cytokine inhibition, as cells from each individual cycle
showed significantly reduced IL-17 production after 72 h of cul-
ture (Figure S5E). The upregulation of proliferation-associated
genes by Arg C and Linezolid led us to wonder if these drugs
were preventing T cells from transitioning to a cytokine-produc-
tion phenotype by maintaining them in a proliferative state. How-
ever, cytokine production was not recovered upon treatment
with any of the tested classes of proliferation inhibitors (Fig-
ure S5F). Therefore, Arg C’s inhibitory effect on cytokine produc-
tion is not merely a consequence of impaired cellular division of
effector cells.
Gfm1 Loss Results in Deficient Mitochondrial
Translation and Impaired Th17 Effector Cell Function
Aside from targeting mitoribosomes, Linezolid is also a weak in-
hibitor of monoamine oxidase (Quinn and Stern, 2009). Also,
Args have been described as inhibitors of the proteasome (Loizi-
dou and Zeinalipour-Yazdi, 2014; Nickeleit et al., 2008). To
exclude that any of these side effects were responsible for the
immunosuppressive effects of these drugs, we genetically tar-
geted mitochondrial protein synthesis in T cells. As the target
of Linezolid is the mitoribosome, which consists of several pro-
teins and rRNAs, we focused instead on Gfm1, the gene encod-
ing mEF-G1, located on chromosome 3 (Gao et al., 2001). Given
that ubiquitous deletion of Gfm1 is lethal at pre-weaning stages,
we generated an inducible, T cell-specific, Gfm1/ mouse
strain (T-Gfm1D). Mice expressing a CD4-specific, tamoxifen-
inducible Cre enzyme (Cd4-creERT2/WT) were crossed with mice
carrying a loxP-flanked exon 4 in the Gfm1 gene (Gfm1flox/flox)
(Figure 5A). Except for amodest increase in the proportion of sin-
gle-positive (SP) CD8+ population within the thymus of T-Gfm1D
mice, immune homeostasis was not significantly affected by any
of the used combinations of Gfm1 and Cd4 transgenic alleles
(Figures S6A and S6B). In contrast to Gfm1/ mice, T-Gfm1DCell Function
conditions in the presence of Arg C or vehicle (DMSO). Cells were stained for
ells (top left) amongst total live CD4+ T cells (bottom left). Right: human CD4+
h17 cell polarizing conditions and treated with Arg C or vehicle (DMSO). Cells
the data of five individual donors, indicated by connected dots. The values
CD4+ cells (below).
g C, Arg F, or vehicle (DMSO) and radioactively labeled with [35S]-methionine.
ions in the presence of Arg C (60 nM), Linezolid (100 mM), or DMSO. (D) Venn
ht) by Linezolid versus Arg C, DMSO versus Arg C, and DMSO versus Linezolid.
ways up or downregulated by both Arg C and Linezolid. (F) Heat maps showing
ent experiments, with error bars representing the SD of the pooled means. *p <
. Genes (E) are included if they were found to be up or downregulated in both
Figure 4. Arg C Treatment Selectively Affects High Proliferating Cells, Leading to Mitochondrial Dysfunction
Naive CD4+ T cells were cultured under Th17 cell polarizing conditions in the presence of Arg C (60 nM), Arg F (60 nM), Linezolid (100 mM), or vehicle (DMSO).
(A) SDHA, ND1, and COX1 were quantified by western blot at the indicated time points.
(B) NAD+/NADH ratio measured at the indicated time points.
(legend continued on next page)
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CD4+ T cells, indicative of functional mitochondrial translation
(Figures 5B and S6C). Upon treatment with 4-hydroxytamoxifen
(4-OHT), COX1 expression dropped in CD4+ T cells from T-
Gfm1D mice in comparison to those still harboring Gfm1 WT al-
leles, either in a haplo-sufficient form (T-Gfm1het: Gfm1flox/WT
Cd4creERT2/WT) (Figure 5B) or lacking Cre-recombinase activity
(Gfm1fl/fl: Gfm1flox/floxCd4creWT/WT) (Figure S6C). Similar to Arg
C, differentiation of 4-OHT-treated naive T cells isolated from
T-Gfm1D mice under Th17 cell-skewing conditions yielded a
significantly reduced frequency of IL-17-expressing cells (Fig-
ures 5C and S6D). Finally, we demonstrated that tamoxifen-
mediated genetic deletion of Gfm1 in CD4+ cells from
T-Gfm1D mice, led to significant protection from the develop-
ment of EAE.Mice retaining a functionalGfm1 allele in CD4+ cells
(T-Gfm1het) were more susceptible to symptoms of the disease
(Figure 5D) and had higher numbers and percentages of MOG-
specific IL-17- and IFN-g-producing Th cells in the CNS (Fig-
ure 5E). Taken together, our results indicate that loss of
mitochondrial translation in T cells, either genetically or pharma-
cologically, restrains Th17 cell function. We further show that
mitochondrial translation is necessary for T cell pathogenicity
in vivo and could represent a therapeutic target to halt Th cell
aberrant responses.
Enabling Mitochondria-Independent NAD+
Regeneration Facilitates Cytokine Production in Arg C
and Linezolid-Treated Cells
Without electron acceptors, cells with dysfunctional mitochon-
dria cannot regenerate cellular NAD+ (Sullivan et al., 2015). As
loss of mitochondrial translation reduces the NAD+/NADH ratio
in differentiating T cells, we hypothesized that facilitating NAD+
regeneration could partially restore cytokine production. To
avoid any metabolic biases due to supplementation of the cul-
ture medium with exogenous metabolites, we supplemented it
with lactate oxidase (Lox), allowing extracellular lactate to be
converted to pyruvate. Pyruvate can then re-enter the cell and
be converted back to lactate, regenerating a molecule of NAD+
in the process (Figure 6A). H2O2 generated by Lox was toxic at
relatively low concentrations of the enzyme (data not shown).
To prevent toxicity, we supplemented the medium with Catalase
(Cat). The addition of both enzymes (LoxCat) rescued IL-17 pro-
duction in both Arg C- and Linezolid-treated cells. This effect
was not mediated by Cat, as Cat-exposed Arg C- and
Linezolid-treated cells failed to produce significant amounts of
cytokines (Figure 6B). LoxCat-exposed cells had a higher IL-17
production and NAD+/NADH ratio than that of the respective
controls (Figures 6B and 6C). Supplementation of the cultureme-
dium with pyruvate equally restored cytokine production (Fig-
ure 6D). To uncouple this phenotype from other potential cellular(C and D) (C) Representative plot of oxygen consumption rate (OCR) at 72 h of cu
addition) respiratory activity of the cells. OCR is reported as picomoles (p
fluoromethoxyphenylhydrazone; Rot, rotenone; AA, antimycin A.
(E) Representative electronic microscopy images show mitochondria morpholog
(F) Cells were stained for intracellular IL-17. The graph shows % of IL-17+ cells a
Statistical significance was determined using two-way ANOVA with Bonferron
one (E) experiments are shown. Results are pooled means of technical replicate
representing the SD of pooled means. *p < 0.05, **p < 0.01, and ***p < 0.001. Se
76 Immunity 54, 68–83, January 12, 2021roles of pyruvate, we supplemented the medium with a-ketobu-
tyrate (a-KB). a-KB can also be reduced by lactate dehydroge-
nase (LDH) to regenerate NAD+ (Sullivan et al., 2015) and was
also able to rescue cytokine production in Arg C- and Line-
zolid-treated Th17 cells (Figure 6D). It has recently been shown
that, when cellular respiration is impaired, serine catabolism
via the mitochondrial folate pathway is responsible for the accu-
mulation of NADH (Yang et al., 2020). Therefore, to understand if
this pathway was responsible for NAD+ depletion (and presum-
ably, loss of cytokine production) upon Arg C and Linezolid treat-
ment, we incubated these cells with DS18561882. DS18561882
is an inhibitor of methylenetetrahydrofolate dehydrogenase 2
(MTHFD2), a mitochondrial enzyme of the folate pathway that
catalyzes an NAD+-consuming step. By treating cells at 24 h of
culture, we hypothesized that we would be able to mitigate the
observed drop in the intracellular NAD+/NADH ratio observed
from 48 h onwards of Arg C or Linezolid treatment (Figure 4B),
and, consequently rescue cytokine production. As surmised,
DS18561882 was able to mitigate the inhibitory effect of Arg C
and Linezolid upon IL-17 production (Figure 6E). Therefore, RA-
bos appear to downregulate Th17 cell function and cytokine pro-
duction by compromising mitochondrial and, consequently,
cellular NAD+-regeneration.
DISCUSSION
It is well established that someRAbos can inhibit mitoribosomes,
and some have been described as immunosuppressive. For
example, Chloramphenicol diminishes neutrophil extracellular
trap release and Doxycycline inhibits B cell class switching and
IgM secretion (Bystrzycka et al., 2017; Kuzin et al., 2001). How-
ever, how the reduction of immune cell function occurred is not
well understood. We have shown here that inhibition of mito-
chondrial protein synthesis by antibiotics can reduce Th cell
cytokine secretion. Certain clinical observations suggest that
Linezolid is immunosuppressive: as previously mentioned, Line-
zolid treatment confers an increased risk of fungal and Gram-
negative infections (Falagas and Vardakas, 2008; Wilcox et al.,
2009). Th17 cell function is necessary for mounting antifungal
and antibacterial responses. As Linezolid is active exclusively
against Gram-positive bacteria, we postulated that Linezolid fa-
cilitates opportunistic fungal or Gram-negative infections by
dampening Th17 cell function. Importantly, we found Linezolid
to inhibit both mitochondrial translation and Th17 cell function
in vitro at concentrations routinely achieved during clinical
administration (Bosso et al., 2004). We also showed that Line-
zolid prevented the development of self-reactive T cells in the
T cell-mediated autoimmunity EAE model. Thus, repurposing
Linezolid as an immunosuppressive drug resulted in significant
protection from pathogenic T cell infiltration and led to absentlture and (D) respective basal (before drug addition) and maximal (after FCCP
mol) of O2 per minute. Oligo, oligomycin; FCCP, carbonyl cyanide-p-tri-
y of Arg C- (60 nM) or DMSO-treated naive T cells from 48 h of culture.
mongst total live CD4+ T cells after 48, 72, and 96 h of culture.
i multiple corrections test. Representative results of three (A), five (C), and
s from three (B and F) and five (D) independent experiments, with error bars
e also Figures S4 and S5.
Figure 5. T Cell-Specific Gfm1 Deletion Attenuates Th17 Cell-Associated Cytokine Production and Mitigates the Development of EAE in
MOG-Immunized Mice
(A) Generation of the CD4-specific, tamoxifen-inducible Cre mouse line. The loxP-flanked exon 4 of the Gfm1 gene is deleted after exposure to tamoxifen.
(legend continued on next page)
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sary to determine if T cell-suppression by Linezolid contributes
to the progression of infections.
To further study the role of mitochondrial translation in T cells,
we searched for alternativemethods to inhibit this process. In light
of the indispensable role ofmEF-G1 in catalyzing the translocation
of mitoribosomes during mitochondrial protein translation (Bhar-
gava et al., 2004; Tsuboi et al., 2009), we made use of Arg C to
hinder mEF-G1’s activity during Th cell differentiation. Murine
mEF-G1 shares 89% sequence identity with the human homo-
logue mEF-G1 (Gao et al., 2001), and accordingly, Arg C was
active against both human and mouse Th17 cells. The similarities
in the gene transcriptional changes of Arg C- and Linezolid-
treated cells further confirmed that targeting mitochondrial trans-
lation with either compound leads to analogous cellular effects.
Using Arg C, we determined that differentiating T cells are highly
reliant on mitoribosomes to keep up with ETC biosynthetic de-
mands. Notably, although Arg C inhibited mitochondrial protein
synthesis after 1 h of treatment, the lack of mitochondrial-en-
coded and -translated ETC subunits was first observed 48 h after
cell activation. At 24 h, themajority of cells had not yet proliferated
(Jelley-Gibbs et al., 2000) and, presumably, did not need to syn-
thesize large amounts of ETC subunits. Between 24 and 48 h,
cell growth anddivisionwould require an increase inmitochondrial
mass and proteome; therefore, an impairment of the mitochon-
drial translation machinery would render cells unable to keep up
with the cellular demand for increased synthesis of ETC subunits.
Ultimately, this would ‘‘dilute’’ pre-existing mitochondrial-en-
coded proteins such as COX1 and ND1 amongst daughter cells.
Consequently, interfering with mitochondrial translation might
deplete mtDNA-encoded proteins more quickly in rapidly dividing
cells such as activated T cells (Fu et al., 2017), while non-prolifer-
ative cells or tissues should be able to retain their ETC subunits for
longer. Accordingly, we showed that naive T cells exposed to Arg
C for as long as 120 h still expressed both COX1 and ND1.
Activated CD4+ T cells in the presence of Arg C, subjected to a
gradual loss of ETC integrity, displayed reduced oxygen con-
sumption and concomitant loss of electron acceptors such as
NAD+. To circumvent this, cells are forced to convert pyruvate
into lactate. As fermentation of glucose into lactate does not
yield net NAD+ (Almeida et al., 2016), over time the concentration
of this cofactor required to support essential oxidative metabolic
reactions in proliferating cells decreases. Accordingly, Th17 cells
treated with Arg C display reducedNAD+/NADH ratios and respi-
ration and increased lactate secretion. Inhibition of mitochon-
drial translation by Arg C did not influence mitochondrial mem-(B and C) Sorted naive CD4+ T cells from T-Gfm1D mice and littermate haplosuffi
maintained in a naive state 12 days prior to being differentiated under Th17 cell ske
cytometry. (B) Representative histograms (left) of COX1 expression amongst CD
relative to DMSO. (C) Representative dot plots (left) show the percentage of IL-
percentage of IL-17+ CD4+ T cells.
(D and E) T-Gfm1D mice and haplosufficient controls were immunized with MOG
twice to every mouse, 3 and 5 days after induction of EAE. The graphs show the
Gfm1het haplosufficient controls.
Bar graphs (B and C) contain the pooled means from the technical replicates of t
means. Plots are obtained from the pooled data of two (D) and three (E) individ
Statistical significance was determined (D) using two-way ANOVA with Bonferron
**p < 0.01, and ***p < 0.001.
See also Figure S6.
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mtDNA, termed r, revealed that these cells display a mitochon-
drial membrane potential high enough to sustain the import of
nuclear-encoded proteins. The mechanism is thought to involve
an electrogenic exchange of ATP4 for ADP3 by the adenine
nucleotide carrier and maintained by an incomplete F1Fo-
ATPase (Appleby et al., 1999; Buchet and Godinot, 1998; Smith
and Thorsness, 2005). The maintenance of mitochondrial mem-
brane potential is also a strong indication that loss of mitochon-
drial translation does not fully compromise mitochondrial or
cellular integrity, which may explain why cellular viability is unaf-
fected by RAbos. Furthermore, ATP consumption tomaintain the
membrane potential is likely to consume glycolysis-derived ATP
and is in agreement with the increased ADP/ATP ratio and de-
gree of AMPK phosphorylation measured in Arg C-treated cells.
Several glycolysis-associated genes were downregulated by
both Arg C and Linezolid when compared to controls in our
RNA-seq data. Themetabolic stress elicited by loss ofmitochon-
drial translation may compromise the upregulation of glycolytic
enzymes that supports anabolic metabolism in differentiating
T cells (Wang et al., 2011). At the same time, inhibited respiration
should place a higher demand for ATP synthesis on the glycolytic
pathway, forcing the cells to convert a higher proportion of pyru-
vate to lactate to preserve the limited NAD+. This may explain
why extracellular pH and lactate concentration are lower and
higher, respectively, in cells with an apparently lower amount
of glycolytic enzymes. Similarly, the RNA-seq data revealed an
upregulation of genes associated with chromosomal replication,
cell cycle, and/or DNA damage checkpoint regulation in Arg C-
and Linezolid-treated Th17 cells. Given that Arg C is mildly
anti-proliferative, it is plausible that loss of mitochondrial transla-
tion leads to replication stress and modulates proliferation at the
transcriptional level during late stages of Th17 cell differentiation.
Nevertheless, our results show that impaired proliferation cannot
explain, per se, the lower degree of cytokine production. Indeed,
upon activation, CD4+ T cells must undergo several rounds of
proliferation to develop into cytokine-producing Th effector cells
(Proserpio et al., 2016). While the loss of COX1 and ND1 occurs
at 48 h, neither proliferation nor IL-17 production is affected at
this time point. Instead, we observed that if mitochondrial trans-
lation remained inhibited, cells progressively stopped producing
IL-17. The downregulation of cytokines became evident from
72 h onwards and occurred in cells from all proliferation cycles,
highlighting that Arg C’s cytokine inhibition and anti-proliferative
phenotypes are uncoupled. In this regard, Arg C appeared to
strictly affect effector function and not initial Th cellcient controls were pre-treated with 300 nM tamoxifen (4-OHT) or DMSO and
wing conditions for 4 days. Intracellular COX1 and IL-17were quantified by flow
4+ T cells. Bar graph (right) shows COX1 median fluorescence intensity (MFI)
17+ amongst live CD4+ T cells. Bar graph (right) shows pooled means of the
35–55 in CFA and pertussis toxin to induce EAE. Tamoxifen was administered
(D) mean clinical scores and (E) CNS-infiltrating cells for T-Gfm1D mice and T-
hree individual experiments, with error bars representing the SD of the pooled
ual experiments, with error bars showing the (D) SEM of the pooled scores.
i multiple corrections test or with (E) an unpaired t test per condition. *p < 0.05,
Figure 6. The Availability of Electron Accep-
tors Restores Cytokine Production in Th17
Cells with Impaired Mitochondrial Respira-
tion
(A) Image depicting the pyruvate-lactate cycling
and consequent intracellular regeneration of NAD+
enabled by exogenous addition of Lox (25 mU) and
Cat (50 U).
(B–E) Naive CD4+ T cells were cultured under Th17
cell polarizing conditions in the presence of the
indicated drugs. The culture medium was supple-
mented with (B and C) Cat alone (Cat) or in combi-
nation with Lox (LoxCat), (D) pyruvate or a-keto-
butyrate (both 10 mM), or (E) DS18561882, and (B,
D, and E) cytokine production and (c) NAD+/NADH
ratios were measured.
Statistical significance was determined using mul-
tiple t tests (A, B, D, and E) or a two-way ANOVA
with Bonferroni multiple corrections test (C). Bar
graphs contain the pooledmeans from the technical
replicates of three (D), four (B and C), and six (E)
individual experiments, with error bars representing
the SD of pooled means. Significance was deter-
mined as follows: *p < 0.05,**p < 0.01, and
***p < 0.001.
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Th1, Th2, and Th17 cells retaining their expression of master
transcription factors T-bet, GATA-3, and RORgt, respectively.
It is now well accepted that mitochondrial metabolism goes
hand-in-hand with T cell differentiation and function. Upon
T cell activation, a metabolic reprogramming occurs, increasing
the rates of glycolysis and respiration (Wang et al., 2011). Oligo-
mycin (a complex V inhibitor) blocks CD4+ T cell proliferation and
activation (Chang et al., 2013), deletion of Uqcrfs1 (a gene en-
coding for a subunit of CIII) impairs IL-2 production upon activa-
tion, andCox10 (a gene encoding for a subunit of CIV) deficiency
compromises T cell activation and proliferation, leading to
apoptosis (Tarasenko et al., 2017). Mitochondria also produce
reactive oxygen species that aid T cell activation (Sena et al.,
2013), and cytokine production in differentiated Th1 and Th17
cells is reduced upon inhibition of specific ETC complexes (Bailis
et al., 2019). Further, mtDNA content increases upon activation,
suggesting that T cell receptor stimulation is coupled to
increased mitochondrial translation (D’Souza et al., 2007; Ron-
Harel et al., 2016). While mEF-G1 is fundamental for mitochon-
drial translation, the transcription and translation of mtDNA-en-
coded genes depend on several other transcription factors and
enzymes (El-Hattab et al., 2017), such as the mitochondrial tran-
scription factor A (TFAM) (Araujo et al., 2018). A former study
from the Mittelbrunn group suggests that T cell-specific deletion
of Tfam (and consequently, loss of mitochondrial translation) im-pairs Th17 and Th2 but exacerbates Th1
cell function (Baixauli et al., 2015). Mice
lacking TFAM in all T cells (Cd4creTfam-
flox/flox [CD4-TFAMD mice]) have more
IFN-g-producing cells in the intestinal lam-
ina propria in a model of DSS-induced in-
testinal colitis (Baixauli et al., 2015). In a
more recent publication, T cells fromCD4-TFAMDmice were shown to expressmore IFN-g and tumor
necrosis factor a (TNFa) than wild-type controls (Desdı́n-Micó
et al., 2020). These mice suffer from multi-organ morbidity and
age and die earlier than wild-type controls; this effect was sug-
gested to be mediated by intracellular NAD+/NADH imbalances.
Possibly, NAD+-sensitive enzymes such as sirtuins or transcrip-
tional regulators like C-terminal-binding protein 1 and 2 can
regulate gene expression in response to a drop in NAD+. How-
ever, if and how this occurs in T cells remains unexamined.
While the studies mentioned above suggest that TFAM defi-
ciency in T cells has systemic autoimmune-like consequences,
CD4-mediated gene deletion models are not specific for Th cells
and also delete the floxed allele(s) in regulatory T (Treg) cells
(Chen et al., 2003; Fontenot et al., 2003). In this regard, the
Zhou group has shown that genetic deletion of Tfam in Treg cells
leads to poor suppressive function and a higher degree of inflam-
mation in a model of T cell transfer colitis (Fu et al., 2019). Treg
cells lacking TFAM (from Foxp3Yfp-creTfamflox/flox [Foxp3-TFAMD]
mice) lose the expression of Foxp3 and produce cytokines such
as IL-17 and IL-13. Th cells from Foxp3-TFAMD mice also ex-
press more IFN-g, TNFa, IL-4, IL-5, IL-13, and IL-17 in different
organs and tissues (Fu et al., 2019). Importantly, while Foxp3-
TFAMDmice experienceweight loss and exhibit a systemic auto-
immunity phenotype starting from 4 to 6 weeks of age, CD4-
TFAMD mice exhibit a milder or no phenotype until 10 weeks of
age (Desdı́n-Micó et al., 2020; Fu et al., 2019). Therefore, deletionImmunity 54, 68–83, January 12, 2021 79
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type observed when this transcription factor is genetically abla-
ted exclusively in Treg cells. Taken together, the results pre-
sented in this paper, as well as those from the Mittelbrunn and
Zhou groups (Desdı́n-Micó et al., 2020; Fu et al., 2019), suggest
that shorter-term inhibition of mitochondrial translation primarily
impairs Th cell function and ameliorates autoimmunity. However,
a longer-term inhibition ultimately appears to compromise Treg
cell functionality. Animal models lacking TFAM specifically in Th
cell subsets, while retaining TFAM-competent Treg cells (and
vice versa), will be necessary to understand how inhibition of
ETC biosynthesis individually affects Th and Treg cells. Further-
more, they would help to understand the pharmacological win-
dow and dose where mitochondrial translation inhibition-medi-
ated immunosuppression overcomes systemic inflammation
due to impaired Treg cell function.
While our results may suggest repurposing RAbos as immuno-
modulatory drugs, this might be a double-edged sword given a
potential negative impact on gut flora (Hagan et al., 2019; Pamer,
2016). Also, widespread usage of Linezolid in an autoimmune
setting might speed up the dissemination of bacterial strains
resistant to this reserveantibiotic. Antibiotics that arenot routinely
used in humanmedicine, suchas Thiamphenicol, couldbe further
explored as immunomodulators. Importantly, Args display poor
antibacterial and antifungal properties and are not currently
used as antibiotics in the clinic (Sasse et al., 2002). Furthermore,
inhibitionofmEF-G1byArgCblockedmitochondrial translation in
Th17 cells at concentrations 4–5 orders of magnitude lower than
Linezolid. Even though we lacked the means to develop a good
in vivo administration method for Arg C, we propose that further
steps should be taken to adapt current or more potent mitochon-
drial translation inhibitors for therapeutic use. To encourage such
efforts, we investigated the role ofmEF-G1 in Th17 cell function in
a T cell-specific Gfm1/ mouse strain. Tamoxifen-mediated
deletion validated thatmEF-G1 is necessary for T cells tomaintain
their effector function. Moreover, deleting Gfm1 in CD4+ cells at
the onset period of EAE induction protected against disease
symptoms and provided strong evidence that this pathway is
necessary for T cell-mediated pathogenicity. In conclusion, our
results provide evidence to consider inhibition of mitochondrial
translation as a method to halt pathological Th cell responses.
Additionally, we identify mEF-G1 as a promising target to control
this cellular process and achieve immunomodulation and high-
light the ability of RAbos to alter host cell functions.STAR+METHODS
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Cermeño, J.C., Villar, L.M., and Guaza, C. (2019). Manipulation of Gut
Microbiota Influences Immune Responses, Axon Preservation, and Motor
Disability in a Model of Progressive Multiple Sclerosis. Front. Immunol.
10, 1374.
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008).
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat.
Methods 5, 621–628.
Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E.G., Mottis,
A., Jovaisaite, V., Frochaux, M.V., Quiros, P.M., Deplancke, B., et al.
(2015). Tetracyclines Disturb Mitochondrial Function across Eukaryotic
Models: A Call for Caution in Biomedical Research. Cell Rep. 10,
1681–1691.
Mutnick, A.H., Biedenbach, D.J., Turnidge, J.D., and Jones, R.N. (2002).
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report
from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn.
Microbiol. Infect. Dis. 43, 65–73.
Nickeleit, I., Zender, S., Sasse, F., Geffers, R., Brandes, G., Sörensen, I.,
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Svensson, V., Pramanik, J., Natarajan, K.N., Zhai, W., Zhang, X., et al.
(2016). Single-cell analysis of CD4+ T-cell differentiation reveals three major
cell states and progressive acceleration of proliferation. Genome Biol. 17, 103.
Quinn, D.K., and Stern, T.A. (2009). Linezolid and serotonin syndrome. Prim.
Care Companion J. Clin. Psychiatry 11, 353–356.
Randle, P.J., Garland, P.B., Hales, C.N., and Newsholme, E.A. (1963). The
glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic distur-
bances of diabetes mellitus. Lancet 1, 785–789.
Richter-Dennerlein, R., Oeljeklaus, S., Lorenzi, I., Ronsör, C., Bareth, B.,
Schendzielorz, A.B., Wang, C., Warscheid, B., Rehling, P., and Dennerlein,
S. (2016). Mitochondrial Protein Synthesis Adapts to Influx of Nuclear-
Encoded Protein. Cell 167, 471–483.e10.
Ron-Harel, N., Santos, D., Ghergurovich, J.M., Sage, P.T., Reddy, A.,
Lovitch, S.B., Dephoure, N., Satterstrom, F.K., Sheffer, M., Spinelli, J.B.,
et al. (2016). Mitochondrial Biogenesis and Proteome Remodeling
Promote One-Carbon Metabolism for T Cell Activation. Cell Metab. 24,
104–117.
Sasse, F., Steinmetz, H., Schupp, T., Petersen, F., Memmert, K., Hofmann, H.,
Heusser, C., Brinkmann, V., von Matt, P., Höfle, G., and Reichenbach, H.
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Chemicals, Peptides, and Recombinant Proteins
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Head-inactivated FCS Biochrom S 0115 – Lot# 1289W
Penicillin-streptomycin Millipore P0781
2-mercaptoethanol Gibco #21985-023
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Recombinant murine IL-1beta Peprotech 211-11B
Recombinant murine IL-12 Peprotech 210-12
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Pertussis Toxin Sigma-Aldrich #180
1X Antibiotic Antimycotic Solution Gibco 15240062
Critical Commercial Assays
EasyStepTM Mouse CD4+ Isolation Kit StemCell technologies 19852
EasySep Human Naive CD4+ T Cell
Isolation Kit
StemCell technologies 19555
Cell Trace Violet Cell Proliferation Kit Invitrogen C34557
LIVE/DEAD Fixable Aqua Dead Cell Stain
Kit, for 405 nm excitation
Thermo Fisher L34957
Seahorse XFe96 FluxPak Agilent 102416-100
Qiagen RNAeasy Kit Qiagen #74106
Oligomycin Sigma-Aldrich 75351
FCCP Cayman 15218
Antimycin A Abcam ab141904
Rotenone Cayman 139995
Lactate Assay kit Sigma-Aldrich MAK064
NAD/NADH-GloTM Assay Promega G9072
ADP/ATP Ratio Assay kit Abcam ab83359
Deposited Data
Raw and processed RNA-seq data Gene Expression Omnibus GSE159401
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Jackson Stock No: 003800
Cd4CreERT2/WT: Cd4tm1(cre/ERT2)Thbu (Sledzinska et al., 2013) N/A
Software and Algorithms
FlowJo software (Tree Star, Inc.) FlowJo LLC https://www.flowjo.com/
Ingenuity Pathway Analysis (IPA, QIAGEN) Qiagen N/A
GraphPad Prism V6 or V7 GraphPad Software https://www.graphpad.com/
QIAGEN’s CLC Genomics Workbench 8 Qiagen N/A
ImageJ N/A N/A
Python matplotlib_venn library Pypi N/A
ComplexHeatmap R package Qiagen N/A
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Materials Availability
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Data and Code Availability
The accession number for the sequencing data reported in this paper is GEO:GSE159401.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6 mice were purchased from Jackson Laboratories.Gfm1flox/flox were generated by crossing mice carrying the heterozygous
Gfm1tm1a(EUCOMM)Wtsi ‘‘knockout first’’ allele (purchased from EMMA mouse repository) with Flp-expressing mice to obtain the con-
ditional allele (Skarnes et al., 2011). T-Gfm1D were generated by crossing Cd4CreERT2/WT (Sledzinska et al., 2013) to Gfm1flox/flox.
Sex- and age-matchedmice between 7 and 20 weeks of age were used for all experiments. All mice were bred andmaintained under
specific pathogen-free conditions at the animal facility of the Helmholtz Center for Infection Research (HZI, Braunschweig, Germany)
or TWINCORE (Hannover, Germany). All animal experiments were performed in compliance with the German animal protection law
(TierSchG BGBl. I S. 1105; 25.05.1998) and were approved by the Lower Saxony Committee on the Ethics of Animal Experiments as
well as the responsible state office (Lower Saxony State Office of Consumer Protection and Food Safety under the permit number
33.9-42502-04-12/0839).
Mouse T cell cultures
CD4+ CD25- T cells were isolated ex vivo from spleens and lymph nodes of mice by enrichment with EasyStepTM Mouse CD4+ Isola-
tion Kit (Stemcell Technologies) in combination with a biotin-conjugated antibody against CD25, followed by immunomagnetic nega-
tive isolation. The purity of the isolated cells was90%. RPMI 1640 GlutaMAXTM medium or IMDMGlutaMAXTM medium (both from
Life Technologies) was used for Th1, Th2, and Treg or Th17 cell cultures, respectively. The medium was supplemented with 10%
heat-inactivated FCS (Biochrom), 500 U penicillin-streptomycin (PAA laboratories), and 50 mM b-mercaptoethanol (Life Technolo-
gies). For Th17 cell induction, 1.5 to 33105 naive T cells were cultured for 4 days with plate-bound aCD3ε (10 mg mL–1, clone
145-2C11; Bio X Cell), aCD28 (1 mg mL–1, clone 37.51; Bio X Cell), aIFN-g (5 mg mL–1, clone XMG1.2; Bio X Cell), aIL-4 (5 mg
mL–1, clone 11B11; Bio X Cell), rhTGF-b1 (2 ng mL–1; Peprotech), rmIL-6 (7.5 ng mL–1; Peprotech), and rmIL-1b (50 ng mL–1; Pepro-
tech). For Th1 induction, 13105 naive T cells were cultured for 4 days in the presence of plate-bound aCD3ε (10 mg mL–1), aCD28
(1 mg mL–1), rmIL-12 (50 ng mL-1), and aIL-4 (5 mg mL–1). For Th2 induction 13105 naive T cells were cultured for 4 days with plate-
bound aCD3ε (10 mgmL–1, clone 145-2C11; Bio X Cell), and aCD28 (10 mgmL–1, clone 37.51; Bio X Cell), aIFN-g (10 mgmL–1, clone
XMG1.2; Bio X Cell), aIL-12 (10 mg mL–1, clone 17.8; Bio X Cell), and rmIL-4 (1 mg mL–1, Preprotech). Arg C, Arg F, Linezolid (Chem-
Impex), Tigecycline hydrate (Sigma), or Thiamphenicol (Chem-Impex) were added at the indicated concentrations at the onset of the
culture. For proliferation analysis, naive T cells were labeled using 5mM CellTrace Violet Cell Proliferation Kit (Life Technologies)
after magnetic sorting.
Human T cell cultures
Human cord blood samples were obtained from the Department of Prenatal Medicine andMidwifery of theMedical School Hannover
(MHH). All work with human blood samples was approved by the local ethics committee and informed consent was obtained from all
subjects. After Ficoll (Biocoll) gradient, naive CD44+ T cells were enriched bymagnetic separation using the EasySepHuman Naive
CD4+ T Cell Isolation Kit (Stemcell Technologies). 53104 T cells were cultured for 6 days in the presence of plate-bound aCD3ε (5 mg
mL–1), in X-Vivo 15 medium (Lonza), supplemented with 2% heat-inactivated FCS (Biochrom), 500 U penicillin-streptomycin (PAA
laboratories), and 50 mM b-mercaptoethanol (Life Technologies). To polarize the cells towards a Th17 cell phenotype, the medium
was supplemented further with rhIL-1b (10 ng mL–1, R&D Systems), rhIL-23 (20 ng mL–1, R&D Systems), rhIL-6 (20 ng mL–1; Pepro-
tech), rhIL-21 (20 ngmL–1; Peprotech), rhTGF-b1 (3 ngmL–1; Peprotech), aCD28 (500 ngmL–1), and 20mMNaCl. Arg C and Linezolid
were added at the indicated concentrations from day 0.
Naive T cell maintenance and Gfm1 deletion
Naive T cells (CD4+ CD25- CD62L+ CD44low) were sorted from spleens and lymph nodes of mice and maintained in RPMI 1640 Glu-
taMAXTM medium (from Life Technologies) supplemented with 10% heat-inactivated FCS (Biochrom), 1X Antibiotic Antimycotic So-
lution (Sigma), and 50 mM b-mercaptoethanol (Life Technologies), containing rmIL-7 (20 ng mL–1, Peprotech). rmIL-7 (10 ng mL–1)
was re-added at the 3rd, 5th, 7th, 9th, and 11th days of culture. To induce tamoxifen-mediated deletion in vitro, (Z)-4-Hydroxytamoxifen
(Sigma) at 300 nMwas added at the beginning of the culture. After 12 days, naive T cells were harvested, counted, and re-plated at a
density of 1.53105 cells per well under Th17 cell-polarizing conditions as described above.
Experimental autoimmune encephalomyelitis
EAE was induced by subcutaneous immunization with 200 mg MOG35–55 peptide (HZI, Braunschweig) emulsified in CFA (Sigma-Al-
drich), followed by intravenous injection of 200 ng pertussis toxin (Sigma-Aldrich) on days 0 and 2. To quantify disease severity,
scores were assigned daily on a scale of 0–5 as follows: 0- no paralysis, 1- limp tail, 2- limp tail and partial hind leg paralysis, 3- com-
plete hind leg paralysis, 4- tetraparesis and 5- moribund or dead. Animals were euthanized if score reached grade 3.5 for twoImmunity 54, 68–83.e1–e6, January 12, 2021 e4
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post-induction and cell suspensions from brain and spinal cord were prepared, as described previously (Berod et al., 2011). Single
suspension of cells were cultured in 48-well plates in the presence of 30mgmL–1MOG35–55 for 2 h followed by addition of Brefeldin A
(5 mg mL–1; Affymetrix/eBioscience) for 4 h. Finally, cells were analyzed by flow cytometry for expression of surface markers and
cytokine production. Where indicated, Linezolid or Vancomycin were administered daily after day 3 post-induction by oral gavage
(4 mg per mouse). Additionally, mice had ad libidum access to drinking water supplemented with 1 mg mL-1 of the indicated anti-
biotic. For COX1 analysis, mice were sacrificed at day 10 post-induction and splenocytes were stained for the markers of interest.
For BrdU incorporation, mice were given 1 mg of BrdU daily (days 9, 10, and 11 post-induction), sacrificed at day 12 post-induction
and splenocytes were stained for the markers of interest. For in vivo deletion of Gfm1 during EAE induction, mice were administered
with two doses of 2 mg of Tamoxifen (Santa Cruz) dissolved in corn oil intraperitoneally, 3 and 5 days after EAE induction.
METHOD DETAILS
Flow cytometry
Monoclonal antibodies against the following mouse antigens were purchased from Affymetrix/eBioscience: CD4 (GK1.5), IL-17A
(eBio17B7), IL-13 (eBio13A), IFN-g (XMG1.2), T-bet (eBio4B10), RORgt (B2D), GATA-3 (TWAJ), FoxP3 (FJK-16s), CD154 (MR1).
COX1 AF488 was purchased from Abcam. For human cells, the following antibodies purchased from Affymetrix/eBioscience
were used: CD4 (SK3), IL-17A (eBio64DEC17). For analysis of surface markers, cells were stained in PBS containing 0.25% bovine
serum albumin (BSA) and 0.02%azide. Dead cells were excluded by LIVE/DEAD Fixable DeadCell Stain Kit (Life Technologies). For
mouse intracellular cytokine staining, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) (0.1mgmL–1; Sigma-Aldrich)
and ionomycin (1 mgmL–1; Sigma-Aldrich) for 2 h followed by brefeldin A (5mgmL–1) for 2 h and fixed using 2%PFA fixation followed
by permeabilization with PBS containing 0.25% BSA, and 0.5% of saponin. Human intracellular staining was done as described
above, but brefeldin A was added simultaneously with PMA and ionomycin instead. For transcription factor staining, cells were
instead fixed with Foxp3/Transcription Factor Fixation/Permeabilization Kit (Affymetrix/eBioscience) according to manufacturer’s in-
structions prior to permeabilization. Stained cells were acquired on a CyAnTM ADP (Beckman Coulter) or an LSR II (Becton Dickinson)
and data was analyzed with FlowJo software (Tree Star, Inc.).
Western blot
Whole-cell lysates were prepared using lysis buffer (PierceRIPA buffer, Thermo Scientific) supplementedwith complete EASYpack
Mini Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor (both from Roche Applied Science). Cell lysates were sepa-
rated by SDS-gel electrophoresis and transferred to PVDF membranes (Merck Millipore). Immunoblotting was performed using the
following antibodies from Cell signaling: mouse anti-b-actin, goat-anti-rabbit (Horseradish peroxidase-conjugated), and anti-mouse
(Horseradish peroxidase-conjugated). The following antibodies were purchased fromAbcam:mouse anti-Sdha, rabbit anti-ND1, and
mouse anti-COX1. Rabbit anti-AMPKa (23A3) and rabbit anti-phospho-AMPKa (Thr172) were purchased from Cell Signaling Tech-
nology, and rabbit anti-HIF-1a was from Novus biological.
Metabolism analysis
Naive CD4+ T cells were plated at a density of 13105 cells per well under Th17 cell-polarizing conditions containing the indicated
drug, harvested after 72 h of culture and plated on 96-well XF cell culture microplates in XF assay medium (pH 7.4, both from Agilent)
supplemented with D-glucose (20 mM), and L-glutamine (2 mM, Gibco) with a density of 33105 cells per well. Microplates were incu-
bated for 30min at 37 C in a non-CO2 incubator and subjected to real-time analysis of OCR using an XF96 Extracellular Flux Analyzer
(Agilent). For the mitochondrial stress assay analysis, the XF Mitochondrial Stress Test was performed according to manufacturer’s
instructions, using subsequent injections of FCCP (0.8 mM), oligomycin (1 mM), and rotenone and antimycin A (0.5 mM).
Mitochondrial membrane potential measurement
Cells were stained at the indicated time points with tetramethylrodamine, ethyl ester (TMRE, Abcam) according to the manufac-
turer’s instructions. After a 20 min incubation with TMRE at 37 C, cells were washed and TMRE was detected by flow cytometry.
Lactate measurement
Lactate concentration in the extracellular medium of T cells cultured under Th17 cell-polarizing conditions for 96 h was performed
using the Lactate Assay kit from Sigma-Aldrich according to manufacturer’s instructions.
NAD+/NADH ratio measurement
NAD+/NADH ratio were measured in T cells cultured under Th17 cell-polarizing conditions for 24, 48, and 96 h using NAD/NADH-
GloTM Assay (Promega) according to the manufacturer’s instructions.
ADP/ATP ratio measurement
The ratio of ADP to ATP were measured in T cells cultured under Th17 cell-polarizing conditions for 96 h using the ADP/ATP Ratio
Assay kit (Abnova) according to the manufacturer’s instructions.e5 Immunity 54, 68–83.e1–e6, January 12, 2021
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EL-4 cells were treated for 1 h with the indicated compounds or vehicle and starved for 20 min before cytosolic translation blocking.
[35S]-Methionine was added to the culture and incubated for 1 h. Cells were subsequently harvested, lysed, and subjected to elec-
trophoretic separation in an SDS-gel. Mitochondrial translation products were detected by autoradiography.
Electron microscopy analysis
Samples were incubated in fixative (2% paraformaldehyde (PFA, EMS), 2.5% glutaraldehyde (GA, EMS) in 0.1 M SodiumCacodylate
(EMS) buffer, pH 7.4) at RT for 30 min. Fixative was removed by washing 5 x 3 min in 0.1 M cacodylate buffer. 100 mL of cell suspen-
sion was embedded by centrifugation (5 min at 1230 g at 30 C) in 100 mL 2% Low Melting Agarose (LMA, Gibco BRL) in 0.1 M ca-
codylate buffer. Samples were then incubated in 2% osmium tetroxide (OsO4, EMS), 1.5% potassium ferricyanide (EMS) in 0.1 M
cacodylate buffer for 60 min at RT. After washing in H2O, samples were incubated in 1% Thiocarbohydrazide (TCH, EMS) in water
for 20 min. TCH was removed by washing 5 x 3 min in water. Then, a second incubation in OsO4 (2% OsO4 in H2O) for 30 min at RT.
After washing in H2O for 5 x 3 min, samples were incubated overnight at 4ºC in Uranyl Acetate Replacement (UA, EMS) in H2O (1:3).
The next day, UARwas removed bywashing in H2O for 5 x 3min. The cells were then incubated for 30min inWalton’s lead solution at
60 ºC. After the washing steps, the samples were dehydrated with EtOH (70%, 90%, and 2x 100%), for 5 min each, followed by 2 x
10 min of propylene oxide (Aldrich). Subsequent infiltration with resin (Spurr, EMS) was done by incubating in 50% resin in propylene
oxide for 2 h, followed by at least 3 changes of fresh 100% resin (including one overnight incubation). Next, samples were embedded
in fresh resin and cured in the oven at 65 C for 72 h. For FIB-SEM imaging, embedded cells were mounted on aluminium SEM stubs
(diameter 12 mm) and samples were coated with 8 nm of Platinum (Quorum Q150T ES). FIB-SEM imaging was performed using a
Zeiss Crossbeam 540 system with Atlas 5 software. The Focussed Ion Beam (FIB) was set to remove 5 nm sections by propelling
Gallium ions at the surface. Imaging was done at 1.5 kV using an ESB (back-scattered electron) detector.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq dataset, quality control, and analysis
The Raw FASTQ files were quality controlled, trimmed, and mapped to theMusmusculus reference genome (GRCm38.p5) using the
RNA-seq Analysis workflow of QIAGEN’s CLC Genomics Workbench 8. Expression was estimated as RPKM (Reads Per Kilobase of
exon model per Million mapped reads) (Mortazavi et al., 2008). Exploratory analysis revealed gene expression patterns following
treatment of naive T cells labelled with CellTrace Violet Cell Proliferation Kit and cultured with DMSO, Linezolid, and Arg C for
96h. Total RNA was isolated using RNeasy Micro Kit (Qiagen) according to the manufacturer’s instructions. Before RNA isolation,
live CD4+ cells which proliferated at least once were sorted from each individual proliferation cycle; cells which had not proliferated
were not included in downstream analyses. Differential expression analysis was performed between the treatment groups. The sta-
tistical significance threshold level of 0.05 with Bonferroni corrected FDR p value and absolute fold change of 2 was used as a cutoff
for differentially expressed genes. We compared the number of overlapping differentially expressed genes from the three treatment
groups at each time points using a proportional Venn-diagram plotted using the Python matplotlib_venn library. Heatmap visualiza-
tion for expression dynamics for the selected genes were plotted using the ComplexHeatmap R package. Pathway analysis was per-
formed by uploading the processed RNA-seq data to Ingenuity Pathway Analysis (IPA, QIAGEN).
Statistical analysis
Data analysis was performed usingGraphPad PrismSoftware. Unless otherwise stated, data were comparedwith a one-way ANOVA
with Bonferroni multiple comparisons test. Means are given as ± standard deviation (SD) or, where indicated, as ± standard error of
the mean (SEM). Significance was determined as follows: *p < 0.05; **p < 0.01, and ***p < 0.001. When appropriate, the values for
different treatments were matched and corrected with the Geisser-Greenhouse method. If values were ±3 SDs (or more) away from
the mean, they were considered as outliers and removed from the dataset.Immunity 54, 68–83.e1–e6, January 12, 2021 e6
